UC BON.CAP.CERT. 09/24 LLY/ DE000HD6AXE8 /
12/08/2024 13:46:12 | Chg.-1.750 | Bid14:34:46 | Ask14:34:46 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
991.220EUR | -0.18% | 992.830 Bid Size: 70 |
995.220 Ask Size: 70 |
ELI LILLY | - - | 27/09/2024 | Call |
GlobeNewswire
01/07
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
28/06
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
21/06
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
19/06
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
12/06
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
11/06
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
11/06
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
11/06
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer an...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
10/06
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...